News|Videos|May 14, 2026

Antibiotic Duration, Treatment Considerations for Lyme Disease in Pediatric Population

In the second installment of our interview with Andrew Handel, MD, he provides insights on Lyme Disease treatment in the pediatric population.

Lyme disease continues to spread into new regions across the United States, prompting renewed educational efforts in May during Lyme Disease Awareness Month. Infectious disease specialists say early recognition and proper treatment remain key to preventing complications from tick-borne illnesses.

Treatment recommendations vary depending on whether a person has simply been bitten by a tick or has developed symptoms of infection. In many cases, patients who experience a tick bite may receive a preventive single-dose course of doxycycline. However, confirmed cases of Lyme disease and other tick-borne infections often require longer antibiotic treatment based on symptom severity.

Andrew Handel, MD, pediatric infectious diseases physician at Stony Brook Children's Hospital and Stony Brook’s Regional Tick-Borne Disease Resource Center in Hampton Bays, NY, explained that treatment duration depends on how the disease presents clinically.

“For Lyme disease in particular, the duration of the treatment depends on the symptoms that you have,” Handel said. “If you have just a single target lesion, a bull’s eye rash, that’s recommended to be treated with 10 days of doxycycline.”

More serious complications, including neurologic symptoms or Lyme arthritis, may require extended treatment courses lasting up to 28 days.

Despite growing concern about Lyme disease nationwide, Handel emphasized that outcomes are overwhelmingly positive for most pediatric patients.

“I always like to remind everyone not to panic,” Handel said. “When their children do have Lyme disease, the vast, vast majority will improve rather quickly with antibiotics, and once they finish their course, very few will have any lingering symptoms.”







Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.